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ABSTRACT 
Tissue engineering bioreactors have been used in order to achieve production of artificial tissue, increasing cell proliferation 
capacity and yield and/or in vitro tissue/disease modelling. Although it is still discussing how to obtain functional and vascular 
tissue with these bioreactors, preclinical and clinical studies are ongoing. Tissue engineering bioreactors have been used as lab-
scale bioreactors until now. Crucial potential application areas can be created by increasing the production capacity and bioprocess 
efficiency of these bioreactors. In this review, recent bioreactor technologies such as spinner flask, rotating wall/bed, hollow fiber 
membrane, perfusion and mechanical stimuli bioreactors are briefly presented in terms of their potential applications in medical 
field especially in the scope of scale-up approaches such as bubble column, stirred tank, membrane, air lift, fluidized packed and 
bed bioreactors. 
Keywords: Bioreactors, modelling in pharmaceutical/biological research, tissue engineering, organ support systems, tailor made 
treatment. 
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INTRODUCTION 
Cell culture has begun to use in medical sciences as 2D 
cell culture accompanying with many disadvantages 
such as not mimicking the in vivo environment, mass 
transfer, gas exchange, waste management, inability to 
real time monitoring of the culture medium, harvesting 
the cells by enzymatic methods and eliminating the cell 
products from the medium during replacement
1,2
. The 
3D culture systems have been enhanced by using 
bioreactors in order to eliminate the disadvantages of 
the static culture. Bioreactor is a system that supports 
biological environment, which designed to gather 
cells/tissues in cell culture. They are developed to use 
in tissue, bioprocess/biochemical engineering. 
Bioreactors can be used for the tailor made treatment, 
the organ support systems, increasing the number of 
cells before autologous cell implantation, in vitro 
tissue/disease modelling in pharmaceutical research 
and producing recombinant human proteins, vaccines, 
drugs and tissue grafts
3,4
. There are different types of 
bioreactors; spinner flask, rotating wall/bed, hollow 
fiber membrane, perfusion and mechanical stimuli 
bioreactors
5
. In this review, recent bioreactor 
technologies for tissue engineering briefly presented in 
terms of their potential applications in medical field 
especially in the scope of scale-up approaches. 
 
TISSUE ENGINEERING BIOREACTORS 
Five types of bioreactors, which can be used for tissue 
engineering are currently in use and commercially 
available. These are; spinner flask, rotating wall/bed, 
hollow fiber membrane, perfusion and mechanical 
stimuli bioreactors
6
. Their mechanisms are briefly 
indicated as follows.  
Spinner Flask Bioreactors 
Spinner flasks are simple and frequently utilized 
bioreactor type. In this system; scaffolds are fixed the 
needles, magnetic bar mixes the medium. Along 
seeding, suspended cells into medium are transferred to 
scaffold throughout by convection. In this way, cell 
seeding performance is increased by 3D seeding 
medium
7
.  
Rotating Wall/Bed Bioreactors 
First discovered rotating wall bioreactor has been 
originally projected by National Aeronautics and Space 
Administration (NASA) in order to gather stable cell 
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culture research in space. At the same time, this is 
revealing a potential for culturing cells on Earth. Wall 
rotation rate allows the centrifugal force, 
hydrodynamic drag force and gravitational force
8,9
.  
Hollow Fiber Membrane Bioreactors 
The bioreactors are frequently utilized for culturing 
sensitive and highly metabolic cells which are needed 
high mass transfer
10
. Hollow fiber membrane 
bioreactors have increased surface for cell attachment. 
Cells can be seeded inner/outer surface of fibers. 
Hollow fiber membrane bioreactors are utilized for 
several purposes; cell population expansion and 
creation of engineered tissues in the field of 
regenerative medicine, in vitro models for drug testing 
in pharmaceutical industry
11
.  
Perfusion Bioreactors 
The perfusion bioreactors have continuous flow and 
oxygenated medium through seeded scaffold which is 
fixed part of bioreactor. These features enhance 
medium flow through scaffold pores also provide 
mechanical stimulus to cells with optimized shear 
stress. In this way, cell function and viability are 
improved
12
. 
Mechanical Stimuli Bioreactors 
There are several types of mechanical stimuli 
bioreactors which are utilize static, dynamic or 
combined effect. Compression bioreactors utilized for 
development of cartilage tissue that are required 
mechanical stimulus for proliferation. In strain 
bioreactors; force applied to the construct is a tensile 
force. These systems are utilized for tendons and 
ligaments engineering
13
. 
Table 1: Application fields, types and examples of bioreactors in medical fields. 
Applications Fields of 
Bioreactors  
Types of Application 
 
Application Examples 
The tailor made treatment 
Organ support systems  
 
 
Bioartificial kidney system
4,18,19  
Bioartificial liver support system
20,21,22,23  
Bioartificial pancreas system
24,25 
Increasing the number 
of cells before 
autologous cell 
implantation 
 
Chondrocyte
26
  
Hepatocyte
27
  
Stem cell
28
  
Platelet rich plasma
29 
Modelling in 
pharmaceutical/biological 
researches 
In vitro tissue 
modelling 
Bone tissue
30
 
Cornealtissue
31 
Skeletal muscle
32
 
Vascular smooth muscle tissue
33 
Micro-Bioreactors, Lab-on-Chips, Organ-on-
Chips
34-40  
Disease modelling 
Modelling fibrosis
41
 
Modelling colon cancer
42 
Modelling acute liver failure
43
 
Modelling chronic obstructive pulmonary 
disease
44 
Modelling lung tumor
45,46 
Modelling malignant peripheral nerve sheath 
Tumor
47 
Disease-on-Chips
48-50  
Human medicinal 
products bioprocess 
Vaccines 
Viral vaccine production (H1N1)
17 
Monoclonal antibodies
51
  
Recombinant human 
proteins 
Recombinant human serum albumin
52
 
Recombinant human insulin
53 
Drugs 
Antibiotics (phenoxymethyl penicillin)
54
 
Citric acid
55
 
Pyruvic acid
56
 
α-Cyclodextrin
57 
Tissue grafts 
Vascular tissue graft
58-62 
Osteochondral graft
63,64
 
Bone graft
65-69 
 
POTENTIAL APPLICATION FIELDS AND 
SCALE UP STRATEGY 
Tissue engineering bioreactors are lab-scale bioreactors 
based on tissue production or modeling. In addition to 
the works carried out to achieve the goal of tissue 
production, other outcomes of these systems were also 
benefited. Scale-up approaches and techniques are 
coming with problems to overcome. These problems 
are also parameters that need to be optimized such as  
 
 
operating time, production efficiency and capacity, 
temperature, pH, oxygenation, continuous monitoring,  
mass transfer, gas exchange, obtaining products and 
control of secondary processes. If repeatable and 
reproducible systems are obtained by optimizing scale-
up conditions, potential applications of bioreactors in 
the medical field can be better succeded
5-13
. 
Considering the usage areas of tissue engineering 
bioreactors and gains, it is seen that these bioreactors 
have potential application capacity. Potential 
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applications arise due to the needs for them. Recent 
potential applications of bioreactors in the medical 
field can be listed as; i. taylor made treatment, ii. in 
vitro tissue/disease modelling in pharmaceutical 
/biological research, iii. producing recombinant human 
proteins, vaccines, drugs and tissue grafts
4,14-17
. 
Although not in the near future; there is a potential that 
tissue/organ printing and personal bioreactor 
producing.
 
 
The Tailor Made Treatment 
Conventional treatment methods include generalized 
protocols based on common indications. On the other 
hand in some clinical scenarios, patients’ individual 
feature and medical charts of patients may vary from 
patient to patient. The tailor made treatment with 
bioreactors can be achieved as application of organ 
support systems and increasing the number of cells 
before autologous cell implantation. Some organs have 
synthesis, filtration, metabolization and detoxification 
function such as kidney, liver and pancreas. In this 
point, the extracorporeal organ supporting systems is 
beneficial, especially on the cell based therapy for 
example; stem cell, platelet rich plasma, autologous 
cell implantation, etc., cell proliferation capacity and 
harvested cell number differ with patient to patient by 
cell origin, age and gender. Because of these individual 
changes, the tailor made treatment has been gained 
importance
14,15
. 
Modelling in Pharmaceutical Research 
Animal studies and their outcomes are naturally piece 
of development of therapeutic systems. However; there 
are some ethical concern come from 3R approach. In 
this point in vitro tissue, disease and physiological 
system modelling are preferable because of saving 
animals and also avoid consuming time, budget and 
working power. Scientists have been still working on 
tissue modelling such as cardiac, liver, pancreas, breast 
and bone tissue modelling in order to work targetted 
organ. On the other way, there are some studies as to 
disease modelling such as bone fracture, damaged 
tissue, cancer tissue in order to work disease based 
therapeutical agents
16
. Multicellular spheroid, hollow 
fiber and multicellular layer are utilized for modelling 
pharmaceutical research such as understanding 
cytotoxicity, drug metabolism and pharmacokinetics
4
. 
Producing Human Medicinal Products 
The batch processing is conventionally utilized in order 
to gather human medicinal products such as vaccine, 
drug and recombinant proteins. In this point, there are 
some concerns about Good Manufacturing Practices 
(GMP) requirements, yield performance, process 
management requirements, monitoring, which also 
must be evaluated in a standardized manner to ensure 
quality control. Some critical parameters such as 
proteomics,surface marker analysis,sterility testing and 
functional assays can be used toensure the quality 
control
15,70,71
. In spite of the mentioned concerns, the 
bioreactors seem to be a good a solution with acoustic 
settlers, hollow fiber bioreactors and hollow fiber 
based perfusion systems including tangential flow 
filtration or alternating tangential flow technologies
17
. 
 
 
CONCLUSION 
The results obtained with tissue engineering 
bioreactors are promising. These systems increase cell 
number and efficiency, cell transplantation 
performance through tissue scaffolds, largely eliminate 
the disadvantages of the 2D cell culture medium, 
ensure real-time monitoring of the cell culture medium 
and achieve graft production. However; there are some 
problems such as lack of repeatability/reproducibility 
in production performance, standardizing treatment 
protocols for transplantation and achieve the same 
efficiency due to patients' different age, gender and 
health status. It is also seen from the studies in the 
literature that functional and vascular structures cannot 
be obtained. On the other hand, GMP requirements and 
legislative infrastructure should be developed in 
advanced therapy medicinal products. Additionally; 
scale-up approaches and techniques are coming with 
problems to overcome. These problems are also 
parameters that need to be optimized such as operating 
time, production efficiency and capacity, temperature, 
pH, oxygenation, continuous monitoring, mass transfer, 
gas exchange, obtaining products and control of 
secondary processes. If repeatable and reproducible 
systems are obtained by optimizing scale-up 
conditions, potential applications of bioreactors in the 
medical field can be better succeeded. From the 
perspective of the future, it is anticipated by the related 
studies that while the developments in bioreactor 
systems continue, there will be significant 
developments regarding the use of plants as bioreactors 
in drug development. 
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